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US-guided transcutaneous tru-cut biopsy
of laryngo-hypopharyngeal lesions
Abstract Objective: To evaluate the
feasibility and performance of
ultrasound-guided transcutaneous
tru-cut biopsy (USGTCB) in selected
patients (with stenosis of airways or
difficult intubation or contraindication
to general anaesthesia) with untreated
or previously treated suspicious
laryngo-hypopharyngeal masses.
Methods: Biopsies were performed
with a free-hand technique by a single
radiologist. Thirty-six USGTCBs
were scheduled in 34 patients (24
males, 10 females; age range 47–
95 years). Two USGTCBs were not
performed, as lesions were not de-
tectable: therefore, 16 USGTCBs
were performed for an untreated mass
suspicious for malignancy and 18
were performed for a mass suspicious
for recurrence after radiotherapy
alone, or associated with endoscopic
laser surgery or chemotherapy.
Results: USGTCB diagnosed
25 squamous cell carcinomas
(73.5%) and nine benign lesions
(26.5%); no false positives and two
false negatives were reported, both
in patients previously treated with
radiotherapy. The sensitivity,
specificity, positive and negative
predictive value of the technique was
92.5%, 100%, 100% and 77.7%
respectively, with no major complica-
tions. Conclusion: Although biopsy
under microlaryngoscopy remains the
“gold-standard” technique, USGTCB
is feasible, carries the advantages of
avoiding general anaesthesia, is
suitable for outpatients and is
cost-effective. If applied to selected
patients, it could be considered for the
histological diagnosis of both primary
and recurrent laryngo-hypopharyngeal
masses.
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Introduction
Trans-cutaneous fine-needle aspiration cytology (FNAC)
and tru-cut biopsy, performed under ultrasound (US) or
computed tomography (CT) guidance, have an important
role in the diagnostic work-up of the head and neck masses
[1–4]. However, the laryngeal space may not be easily
accessible with a transcutaneous approach and biopsies of
the masses in this district are usually performed by
microlaryngoscopy, in order to obtain material for histolog-
ical diagnosis and to assess the feasibility of conservative
surgery. There are, however, some technical limitations to
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this approach: the intubation could be difficult in patients
with large masses obstructing the upper airways and the
biopsy procedure is often complicated by breathing
difficulties due to haemorrhage or oedema. For such reasons,
a protective tracheotomy may be required.
Trans-oral laryngeal biopsy under local anaesthesia is an
alternative approach when a patient has a contraindication to
the general anaesthesia; however, it may be difficult in
patients with largemasses obstructing the airways and it may
be burdened with specimen inadequacy problems when
performed for a suspected recurrence after radiotherapy (RT)
or chemo-radiotherapy [5–7].
A pilot study from Ansarin et al. [5] showed that
ultrasound-guided transcutaneuos tru-cut biopsy (USGTCB)
is a feasible technique for the diagnosis of bulky laryngo-
hypopharyngeal masses in patients who have a contraindi-
cation to general anaesthesia (e.g. patients at high risk for
serious co-morbidity or multiple concomitant malignancies
in the oro-pharyngeal area) and in patients who would not be
candidates for conservative surgery if the mass was malig-
nant, overcoming the disadvantages of FNAC. In fact, the
cytological sample is unable to differentiate in situ from
invasive carcinoma and is often inadequate or falsely
negative in patients already treated with RT or chemo-
radiotherapy [8, 9].
The purpose of this study was to evaluate the feasibility
of USGTCB in patients with untreated or previously
treated suspicious laryngo-hypopharyngeal masses and to
evaluate its performance for obtaining a histological
diagnosis.
Materials and methods
Patients
This study was approved by our institutional ethics
committee and a written informed consent was obtained
from all patients prior to starting the study.
Between August 2004 and February 2008, patients with
untreated or previously treated suspicious laryngo-hypopha-
ryngealmasseswere prospectively enrolled in the study if the
following criteria were met: (1) stress dyspnoea due to a
stenosis of airways, which would have required a protective
tracheotomy for a microlaryngoscopy under general anaes-
thesia; (2) signs indicating difficult intubation [10, 11] or (3)
relative contraindication to general anaesthesia; (4) CT or
magnetic resonance imaging (MRI) of the head and neck
performed within 1 month before the procedure.
Patients without a history of malignancy were included if
they had a mass in the larynx or hypopharynx (only piriform
sinus subsite) suspicious ofmalignancy thatwas staged as T3
or T4 at clinical and/or cross-sectional imaging by CT or
MRI, or if they had bulky T2 lesions of the supraglottic
larynx. Patients with a history of tumors in the larynx or
hypopharynx, treated with RT, chemotherapy and/or surgery
were included if they had a laryngo-hypopharyngeal mass
suspicious of recurrence at clinical examination and/or CTor
MRI follow-up.
Patients excluded were those with massively calcified
thyroid cartilage, those with cT1 disease, those with
superficial glottic cT2 lesions not detectable by ultrasound
and those with an abnormal coagulation profile including
prothrombin activity (PA), partial thromboplastin time (PTT)
and international normalized ratio (INR), with normal values
being respectively 70–120%, 17–26 s, and 0.8–1.2.
Technique
All biopsies were performed with the free-hand technique
by a single radiologist (blinded for review) with 10 years
experience in free-hand US-guided biopsies.
The first step of the USGTCB was the evaluation of
the CT or MR images, to localize the mass candidate to the
procedure and to have a panoramic assessment of the
anatomic structures adjacent to the mass, in order to identify
a potential path for the needle.
The second step was accurate patient positioning: all
patients laid in the supine position on a bed reclined at 35°
and with the head (hyper)extended. The skin was
disinfected with antiseptic and covered with a sterile drape.
The third step was the assessment by US of the mass in
the larynx or hypopharynx, in order to evaluate: first, if the
mass was visible with US and, second, if it was possible to
identify a safe path for the needle. The US examination also
included an assessment with the colour-Doppler technique,
in order to identify vessels adjacent to the mass or
eventually crossing the hypothesized path of the needle.
All the US exams, including colour-Doppler study, were
performed on a Sequoia 512 USG machine (Siemens,
Erlangen, Germany), using a multifrequency linear 15L9W
probe (Siemens, Erlangen, Germany).
If the mass was visible at US and judged as a candidate for
the USGTCB, an 18-gauge cannula was placed in the
antecubital vein and local anaesthesia (10 ml of 2%
carbocaine) was performed in the tissues along the
hypothesized path of the needle as well as in the subcuta-
neous tissues, using a 22-gauge spinal needle (Terumo
Medical Corporation, Tokyo, Japan). Intravenous sedation or
analgesia was never performed.
For the lesions at the supraglottic level, a path was
selected for the needle through the thyrohyoid membrane;
for the glottic and subglottic lesions a path through the
cricothyroid ligament; for lesions of the piriform sinus a
path lateral to the free edge of the thyroid cartilage. If the
full thickness of the cartilage was infiltrated, the needle was
introduced directly through it.
Once the path for the needle was selected, a 16- or
18-gauge spring-loaded biopsy needle (Biopsy-bell,
Mirandola, Italy) was used for the biopsy under US
guidance.
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At the end of the procedure the patients were kept at rest
in the recovery room for 30 min and then discharged if no
complications arose.
Tissue cores were placed in 10% phosphate-buffered
formalin for 12 h, paraffin embedded and sectioned at 4
µm, followed by standard stain with hematoxylin and eosin
(H & E); when required, a immunohistochemical stain was
also performed, for a better evaluation of the neoplasm and
comprehension of histological type.
Results
From the 40 patients who were canditates for the
USGTCB, six (15%) were excluded for the following
exclusion criteria: two for massively calcified thyroid
cartilage, four for the presence of a glottic cT2 disease.
Therefore, 36 USGTCBs were scheduled in 34 patients
(24 males, 10 females; mean age 65 years, range
47–95 years); in two patients who met the inclusion criteria,
the procedure was scheduled both for the first diagnosis and
for a suspicious recurrence of squamous cell carcinoma
(SCC), after RT in one case and after chemo-radiotherapy in
the other.
Two USGTCBs were not performed in two patients (one
with cT2 untreated supraglottic laryngeal mass and one
with suspected T3 laryngeal recurrence), as lesions were
not detectable by US. Therefore, a total of 34 USGTCBs
were performed in 32 patients: 16 USGTCBs were
performed for an untreated mass suspicious of malignancy,
including 12 masses in the larynx (two cT2, seven cT3 and
three cT4) and four masses in the piriform sinus (three cT3
and one cT4), and 18 USGTCBs were performed for a
mass suspicious of recurrence (two cT2, eight cT3, eight
cT4) after endoscopic laser surgery and RT in 13 cases, RT
alone in three cases and chemo-radiotherapy in two cases.
A 16-gauge core biopsy needle was used in 14 procedures
and an 18-gauge core biopsy needle in 20 procedures.
None of the enrolled patients developed cancer cell
dissemination due to USGTCB. All the 34 specimens
obtained with the USGTCB were sufficient for diagnosis.
At pathology, lesions were diagnosed as invasive SCC
(73.5%) in 25 cases (true positives) (Fig. 1) and as benign
in nine cases (26.5%), including postradiotherapy fibrosis,
in all cases, associated with chondronecrosis in two
patients. Fifteen out of the 25 SCCs underwent subsequent
surgery, which confirmed the diagnosis of malignancy;
the remaining ten SCCs were treated with chemo-
radiotherapy and followed-up with clinical examination
and CT or MRI.
The nine benign lesions were all diagnosed in patients
previously treated with RT alone or associated with
endoscopic laser surgery or chemotherapy; in seven of
them (true negatives) (Fig. 2), the diagnosis was confirmed
by surgery in two cases and by follow-up (mean follow-up
22 months, range 13–28 months) in five cases, whereas in
the remaining two cases (false negatives) (Fig. 3) a
subsequent surgical biopsy did not confirm the diagnosis
performed with the tissue cores from the USGTCB,
showing the presence of SCC. No false positive result
was reported.
Overall, the sensitivity of the technique was 92.5%; the
specificity was 100%; positive and negative predictive
values were 100% and 77.7%, respectively.
Sensitivity, specificity, positive and negative predictive
value for the 18 procedures with the suspicion of recur-
rence were 81.8%, 100%, 100% and 77.7%, respectively.
The time required for the USGTCB ranged from 15 to 24
min (mean time 18 min). We did not observe major
complications, according to the categorization of the Society
of Interventional Radiology [12]. One patient, who under-
went USGTCB for the suspicion of laryngeal recurrence 2
years after RT, developed a near-syncope, which resolved
spontaneously.
Fig. 1 A patient with suspected
recurrence of SCC of the larynx
after RT. a CT shows an
enhancing lesion of the right
vocal cord causing wide erosion
of the thyroid cartilage and
involvement of the adjacent soft
tissue. b USGTCB obtained
using a semiautomated
18-gauge biopsy needle
(white arrow), which has been
introduced into the lesion
through the disrupted thyroid
cartilage
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Discussion
The biopsy obtained by microlaryngoscopy under general
anaesthesia is the diagnostic approach of choice in patients
with a suspected laryngo-hypopharyngeal mass.
In clinical practice there are categories of patients to
whom the use of such a diagnostic procedure is risky or
charged by an elevated percentage of false negatives
[13, 14].
On the basis of the pilot study by Ansarin et al. [5], we
have prospectively enrolled for USGTCB selected patients
with laryngo-hypopharyngeal masses newly diagnosed or
suspicious of recurrence after RT alone or associated with
surgery or chemotherapy. USGTCB was feasible in 32 out
of the 34 patients who met the inclusion criteria and were
scheduled for the procedure. The rigid selection of the
patients candidate to the USGTCB and the accurate review
of the previous radiological examinations (CT or MRI)
prior to the procedure may account for the feasibility of the
procedure observed in our series. In the two patients who
met the inclusion criteria (one with untreated cT2 lesion
and the other with suspected T3 glottic recurrence after RT)
but did not undergo USGTCB, the procedure was not
feasible, as in both cases the mass was not detectable due to
a limited acoustic window, caused by a calcified thyroid
cartilage. The thyroid cartilage is the most important
anatomical obstacle in patients referred for USGTCB,
especially in adults, in whom it is largely calcified and
could not easily be crossed by the needle. In those cases, in
order to reach the lesions it is necessary that the area of
Fig. 2 A patient with clinical
suspicion of recurrence in the
glottic-subglottic region after
endoscopic laser surgery and
RT. a CT at the level of the
subglottis, showing enhancing
soft tissue anteriorly causing
airway stenosis. b US image
obtained in the same plane,
showing the needle tip within
the lesion (markers 1 and 2
indicating calipers used to
measure the lesion). Histopa-
thology was compatible with
fibrotic tissue associated with
inflammatory changes. The
diagnosis was then confirmed
by endoscopic surgery
Fig. 3 A patient who was treated 1 year before with chemo-
radiotherapy for laryngeal SCC, presenting with swelling of the left
false vocal cord region. a CT at the supraglottic level showing a
submucosal soft tissue mass with inhomogeneous enhancement on
the left side suspicious for tumour recurrence. b US image showing
the tip of the tru-cut needle on the left side of the supraglottis.
Histopathology was inconclusive for tumour recurrence. The final
diagnosis of recurrence was obtained by multiple biopsies under
microlaryngoscopy during general anaesthesia and the patient then
underwent total laryngectomy
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erosion due to tumour spread is sufficiently wide to obtain
a proper sample.
The long experience of the radiologist that performed all
the USGTCBs in this study may have contributed to the
feasibility of the procedure. We believe that an extensive
knowledge of the regional anatomy and a suitable expe-
rience in the execution of free-hand biopsy procedures
under US guidance are mandatory to safely perform
USGTCB. When the procedure was feasible amongst the
eligible patients with an untreated laryngeal-hypopharyn-
geal mass (in 16 patients), the samples were diagnostic in
all cases.
The choice of the needle size, 16- or 18-gauge, was
based upon the dimension of the lesion and the size of the
acoustic window.
When the USGTCB was performed on masses suspicious
for recurrence, two false-negative results out of 18
procedures were observed, with a sensitivity of 81.8%.
Both false-negative patients, however, had a previous history
of radiotherapy treatment and it is known that previous
(chemo)radiotherapy may impair the diagnosis of recurrence
and that the most reliable technique to obtain a histological
diagnosis would be via microlaryngoscopy under general
anaesthesia [15]. The assessment of recurrent laryngeal
carcinoma after (chemo)radiotherapy is much more difficult
than the assessment of “de novo” carcinoma either by
endoscopy or by imaging studies for various reasons: tumour
may recur after radiation therapy in multicentric foci,
undetectable by imaging studies, residual inflammation
changes may be associated with radiotherapy, tumour
recurrence may be localised submucosally and invisible
during endoscopy [16]. Often, symptoms and signs for
tumour recurrence and radionecrosis are identical and
patients undergo numerous inconclusive endoscopy
procedures [17]. In many of these cases the radiological
findings typical for chondro-radionecrosis, such as progres-
sive crico-arytenoid sclerosis, presence of gas bubbles as
well as fragmentation and collapse of cartilages, are not
present [18]. In contrast, the appearance of areas of focal
contrast enhancement not present at prior imaging exams
may be suspicious but not specific for tumour recurrence [17,
19]. Although some authors recommend 18F-fluorodeox-
yglucose positron emission tomography (18F-FDG-PET) for
post-treatment imaging [20], its value is currently not firmly
established [21], as possible false-positive results may occur
because of therapy-induced inflammatory changes and
false-negative results may occur due to its low spatial
resolution [22]. Diffusion-weighted MRI (DW-MRI) has
shown in initial experiences a high accuracy for tissue
differentiation in the post-RT phase independently from
inflammatory or necrosis-induced tissue distortions [21].
Since both modalities are able to diagnose a recurrence at an
early stage, they can potentially avoid delay of treatment,
reducing the risk of disease progression and, therefore,
improving patient management. However further studies,
ideally with a larger patient population are needed.
In our two false-negative cases, CT was able to show
focal areas of contrast enhancement greater than 1 cm
within the original tumour bed, involving the glottic
region; the diagnosis of recurrence was obtained in both
cases with multiple biopsies by microlaryngoscopy under
general anaesthesia. The two patients then underwent total
laryngectomy, with the post-operative diagnosis of pT2 and
pT3 SCC.
In conclusion, in our study USGTCB was a feasible
technique, which has the advantages of avoiding general
anaesthesia, being suitable for outpatients and being cost-
effective when compared with the alternative techniques.
In our study, USGTCB provided adequate specimens for
histological analysis, including immunohistochemical
methods, thus showing good performance for obtaining a
histological diagnosis of untreated or previously treated
laryngo-hypopharyngeal masses suspicious of malignancy.
If it were applied to selected patients, USGTCB could be
considered for the histological diagnosis of both primary
and recurrent hypopharyngeal and laryngeal masses before
performing the biopsy under general anaesthesia using
microlaryngoscopy.
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